{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T02:02:05Z","timestamp":1785722525706,"version":"3.56.0"},"reference-count":42,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:p>\n                    The aim of this review is to summarize the clinical efficacy, tolerability and safety data of insulin detemir, and compare its use with that of neutral protamine Hagedorn (NPH) insulin in randomized controlled trials in people with type 1 or type 2 diabetes. A literature search was conducted with\n                    <jats:styled-content style=\"fixed-case\">PubMed<\/jats:styled-content>\n                    using predefined search terms. Studies were included if they met the following criteria: randomized, controlled trial, comparison of insulin detemir with\n                    <jats:styled-content style=\"fixed-case\">NPH<\/jats:styled-content>\n                    insulin, non\u2010hospitalized adults aged \u226518\u2009years with either type 1 or type 2 diabetes, and study duration of \u226512\u2009weeks. The following types of studies were excluded: non\u2010randomized controlled trials, studies of mixed cohorts of patients with type 1 or type 2 diabetes that did not report results separately, pharmacokinetic\/pharmacodynamic studies, reviews, pooled or meta\u2010analyses or health\u2010economic analyses. Fourteen publications met the inclusion criteria. Nine studies in people with type 1 diabetes and three studies in people with type 2 diabetes, using insulin detemir in a basal\u2013bolus regimen were included. Two studies were in people with type 2 diabetes using insulin detemir with oral antidiabetes medicines. In 14 studies of people with type 1 or type 2 diabetes, insulin detemir treatment provided similar or better glycaemic control, lower within\u2010subject variability, similar or lower frequency of hypoglycaemia and less weight gain when compared with NPH insulin.\n                  <\/jats:p>","DOI":"10.1111\/dom.12106","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T00:31:31Z","timestamp":1365035491000},"page":"978-986","source":"Crossref","is-referenced-by-count":42,"title":["A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review"],"prefix":"10.1111","volume":"15","author":[{"given":"B. M.","family":"Frier","sequence":"first","affiliation":[{"name":"BHF Centre for Cardiovascular Science, The Queen's Medical Research Institute University of Edinburgh  Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Russell\u2010Jones","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology Royal Surrey County Hospital &amp; University of Surrey  Guildford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Heise","sequence":"additional","affiliation":[{"name":"Profil  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006817"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2007.00756.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1911"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00685.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2007.10.007"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2009.08.005"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.11.019"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:PHAM.0000036926.54824.37"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2007.02407.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2004.03.003"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc05-1365"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.5.1081"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90072-0"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2005.01545.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.590"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2004.00363.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2004.6.579"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2004.00373.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02483.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01862.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.10.020"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1365-z"},{"key":"e_1_2_7_24_1","first-page":"455","article-title":"Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study","volume":"57","author":"Calvert MJ","year":"2007","journal-title":"Br J Gen Pract"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.10.2543"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02176.x"},{"key":"e_1_2_7_27_1","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry: Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention (Draft guidance) 2008. Available from URL:http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatory Information\/Guidances\/ucm071624.pdf. Accessed 6 December 2012."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X260835"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01939.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-1916-y"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.6.1614"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00874.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01839.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.5.1107"},{"issue":"1","key":"e_1_2_7_35_1","first-page":"A120","article-title":"Insulin detemir reduces hypoglycemic risk at comparable HbA1c values compared to NPH in patients with type 1 diabetes","volume":"54","author":"Heller S","year":"2005","journal-title":"Diabetes"},{"issue":"1","key":"e_1_2_7_36_1","first-page":"A302","article-title":"Insulin detemir incurs a lower risk of hypoglycaemia than NPH insulin for any level of HbA1c when added to oral agents in a treat\u2010to\u2010target protocol for patients with type 2 diabetes","volume":"48","author":"K\u00f8lendorf K","year":"2005","journal-title":"Diabetologia"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-s220"},{"key":"e_1_2_7_38_1","first-page":"CD006383","article-title":"Insulin detemir versus insulin glargine for type 2 diabetes mellitus","volume":"7","author":"Swinnen SG","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2010.0063"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0098"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-1670-1"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1487-4"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-1493"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12106","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:04:55Z","timestamp":1761879895000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1111\/dom.12106"],"URL":"https:\/\/doi.org\/10.1111\/dom.12106","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}